Sadda, SriniVas http://orcid.org/0000-0002-4939-3306
Holekamp, Nancy M.
Sarraf, David
Ebraheem, Adel
Fan, Wenying
Hill, Lauren
Blotner, Steve
Spicer, Galin
Gune, Shamika
Funding for this research was provided by:
Genentech Inc
Article History
Received: 23 February 2022
Revised: 8 May 2022
Accepted: 27 May 2022
First Online: 10 June 2022
Declarations
:
: The HARBOR trial was conducted in accordance with Good Clinical Practice (International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use [ICH] E6), applicable US Food and Drug Administration regulations, the Health Insurance Portability and Accountability Act, and the tenets of the Declaration of Helsinki. The trial protocol was approved by institutional review boards and ethics committees as applicable.
: Written informed consent was obtained from all participants in the HARBOR trial.
: Not applicable.
: SriniVas Sadda has served as a consultant for Allergan, CenterVue, Genentech, Inc., Heidelberg, Iconic, Novartis, Optos, and ThromboGenics, and has received grant or financial support from Allergan, Carl Zeiss Meditec, Genentech, Inc., Optos, and Topcon. Nancy M. Holekamp has served as a consultant for Acucela, Allergan, Apellis, Bayer, Clearside Biosciences, Gemini, Genentech, Inc., Gyroscope, Katalyst Surgical, Lineage Cell Therapeutics, Nacuity, Notal Vision, Novartis, PolyActiva, and Regeneron. David Sarraf has served as a consultant for Amgen, Bayer, Genentech, Inc., Iveric Bio, and Optovue; has received research support from Genentech, Inc., Heidelberg, Optovue, Regeneron, and Topcon; and has been a speaker for Novartis and Optovue. Adel Ebraheem and Wenying Fan have no conflicts of interest to disclose. Lauren Hill has served as a consultant for Aerpio, Alimera, Genentech, Inc., PolyPhotonix, and Recens Medical. Steve Blotner, Galin Spicer, and Shamika Gune are employees of Genentech, Inc.